Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data - Response

被引：0
|
作者：
Gringeri, A [1 ]
机构：
[1] Mangiagalli & Regina Elena Hosp Fdn, IRCCS Maggiore, A Bianchi Bonomi Haemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 130卷 / 01期
关键词：
B-domain-deleted FVIII; haemophilia A; inhibitors; recombinant FVIII;
D O I：
10.1111/j.1365-2141.2005.05552.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：146 / 147
页数：3
相关论文
共 50 条
  • [1] Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data
    Larson, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) : 145 - 146
  • [2] Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII
    Gringeri, A
    Tagliaferri, A
    Tagariello, G
    Morfini, M
    Santagostino, E
    Mannucci, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (03) : 398 - 404
  • [3] Antibody and inhibitor patterns in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant factor VIII (BDDrFVIII).
    Lusher, JM
    Petrini, P
    Angiolillo, A
    Nguyen, K
    Nissen, S
    Wikén, M
    Rup, B
    Bedrosian, CL
    BLOOD, 2000, 96 (11) : 266A - 266A
  • [4] Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted recombinant FVIII (BDDrFVIII).
    Lusher, JM
    Gringeri, A
    Hann, I
    Rodriguez, D
    BLOOD, 1999, 94 (10) : 234A - 235A
  • [5] The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
    Lusher, JM
    Lee, CA
    Kessler, CM
    Bedrosian, CL
    HAEMOPHILIA, 2003, 9 (01) : 38 - 49
  • [6] Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A
    Kempton, C. L.
    Abshire, T. C.
    Deveras, R. A.
    Hoots, W. K.
    Gill, J. C.
    Kessler, C. M.
    Key, N. S.
    Konkle, B. A.
    Kuriakose, P.
    Macfarlane, D. E.
    Bergman, G.
    HAEMOPHILIA, 2012, 18 (05) : 798 - 804
  • [7] Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients
    Roussel-Robert, V
    Torchet, MF
    Legrand, F
    Rothschild, C
    Stieltjes, N
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (11) : 2450 - 2451
  • [8] Inhibitor development in previously treated patients with hemophilia A after switch to recombinant factor VIII
    Wu, Y.
    Tsay, W.
    Lin, H.
    Chang, C.
    Chen, M.
    Shen, M.
    HAEMOPHILIA, 2008, 14 : 52 - 53
  • [9] The use of recombinant factor VIII products in previously treated patients with hemophilia A: Pharmacokinetics, efficacy, safety, and inhibitor development
    Lee, C
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03): : 241 - 246
  • [10] Safety and efficacy of ReFacto, the B domain-deleted recombinant factor VIII (BDDrFVIII), in home therapy of previously treated patients (PTPs) with severe hemophilia A: An Italian multicenter trial.
    Gringeri, A
    Tagliaferri, A
    Bellatreccia, A
    Bianchi, C
    Mannuccio, PM
    BLOOD, 2000, 96 (11) : 262A - 262A
12345